Longeveron (LGVN) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
November 10, 2023 7:30 AM ESTTop Line Results from CLEAR MIND Alzheimers disease Trial Affirm Safety Profile of Lomecel-B and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks
Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association
$4 Million in Equity Financing Secured in Registered Direct Offering
ELPIS II Phase 2 Trial of Lomecel-BÂ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024
Company to Hold Conference Call and Webcast Today, November... More
